Evidence for BCR-ABL-dependent dysfunctions of iNKT cells from chronic myeloid leukemia patients-Reference-Cited by-同舟云学术

Evidence for BCR-ABL-dependent dysfunctions of iNKT cells from chronic myeloid leukemia patients

Published:2012-07 Issue:7 Volume:42 Page:1870-1875
ISSN:0014-2980
Container-title:European Journal of Immunology
language:en
Short-container-title:Eur. J. Immunol.

Author:

Rossignol Alexis,Levescot Anaïs,Jacomet Florence,Robin Aurélie¹,Basbous Sara,Giraud Christine,Roy Lydia,Guilhot François,Turhan Ali G.,Barra Anne,Herbelin André,Gombert Jean-Marc

Affiliation:

1. INSERM UMR S1082; Poitiers; France

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/eji.201142043/fullpdf

Reference24 articles.

1. Chronic myeloid leukemia advances in biology and new approaches to treatment;Goldman;N. Engl. J. Med.,2003

2. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia;O'Brien;N. Engl. J. Med.,2003

3. Five-year follow-up of patients receiving imatinib for chronic myeloid leukaemia;Druker;N. Engl. J. Med.,2006

4. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia;Molldrem;Nat. Med.,2000

5. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia;Sacchi;J. Clin. Oncol,1995

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Case report: Long-term voluntary Tyrosine Kinase Inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML): Molecular evidence of an immune surveillance;Frontiers in Oncology;2023-03-16

2. Virtual Memory CD8⁺ T Cells: Origin and Beyond;Journal of Interferon & Cytokine Research;2022-12-01

3. Treatment-Free Remission—A New Aim in the Treatment of Chronic Myeloid Leukemia;Journal of Personalized Medicine;2021-07-22

4. Translating Unconventional T Cells and Their Roles in Leukemia Antitumor Immunity;Journal of Immunology Research;2021-01-07

5. Innate T-αβ lymphocytes as new immunological components of anti-tumoral “off-target” effects of the tyrosine kinase inhibitor dasatinib;Scientific Reports;2020-02-24